Citations

Clear

2368 citation(s) found for "Su, Jack".

Diffusion MRI Identifies a Prolonged Pre-WMH Phase in Cerebral Small Vessel Disease
Hu, Mingzhao, Lundt, Emily S. , Kamykowski, Michael G. , Reid, Robert I. , Tm, Therneau, Raghavan, Sheelakumari , Cogswell, Petrice M., Griswold, Michael , Windham, B. Gwen, Petersen, Ronald C. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lundt, Emily S , Kamykowski, Michael G , Reid, Robert I , Raghavan, Sheelakumari , Griswold, Michael , Jack, Clifford R , Petersen, Ronald C , Graff-Radford, Jonathan , Vemuri, Prashanthi , Hu, Mingzhao, Cogswell, Petrice M. , Windham, B. Gwen , Jack, Clifford R.

Mayo Clinic

Stroke | July 22, 2026 | Volume: 57 | Issue: 9 | Pages: 2789-2800

10.1161/strokeaha.126.055797 | PMID 42483814 Get It

BACKGROUND: White matter hyperintensities (WMH) are widely used to assess cerebral small vessel disease but reflect late-stage injury. Diffusion magnetic resonance imaging (MRI) biomarkers have been proposed to capture earlier small vessel disease-related microstructural damage but their temporal progression relative to WMH and risk factors associated with progression remain unexplored. METHODS: We identified 2077 participants from the population-based cohort study of the Mayo Clinic Study of Aging in Olmsted County, Minnesota (aged 50–101 years) collected between 05/2005 and 09/2024 with longitudinal neuroimaging. Using multioutput nonlinear mixed-effects models in those with at least 2 fluid-attenuated inversion recovery-MRI and diffusion MRI scans, we characterized the temporal progression of WMH and 4 diffusion MRI biomarkers: fractional anisotropy of the genu of the corpus callosum, peak width of skeletonized mean diffusivity, free water, and Arteriolosclerosis-score, which were automatically estimated. Models incorporated participant-specific time shifts, correlations between biomarkers, and effects of risk factors (sex, education, APOE ε4 status, cardiometabolic conditions). RESULTS: The study population had a mean age of 78 years, 47% were women, 28% were APOE ε4 allele carriers, and 80% were cognitively unimpaired, with an average follow-up of 5.2 years (SD, 4.3 years) for fluid-attenuated inversion recovery-MRI and 4.3 years (SD, 3.9 years) for diffusion MRI. Arteriolosclerosis-score, fractional anisotropy of the genu of the corpus callosum, free water, and peak width of skeletonized mean diffusivity became abnormal in 50% of the study population 16, 12, 10, and 7 years before WMH become abnormal (half-width of CI <1 year), respectively. Global markers (Arteriolosclerosis-score, free water, peak width of skeletonized mean diffusivity, and WMH) were correlated, indicating shared substrates of widespread white matter injury. Fractional anisotropy of the genu of the corpus callosum, a vascular risk microstructural injury biomarker, was weakly coupled with WMH and had an earlier but more linear worsening across adulthood. Cardiometabolic conditions predicted earlier worsening of all biomarkers. Female participants showed earlier WMH, fractional anisotropy of the genu of the corpus callosum, and Arteriolosclerosis-score abnormalities, whereas male participants exhibited earlier peak width of skeletonized mean diffusivity and free water abnormalities. CONCLUSIONS: Diffusion MRI biomarkers were abnormal at least a decade before WMH become abnormal in the population, revealing a prolonged phase of early small vessel disease and highlighting their potential for small vessel disease prevention.
Relationships of CSF biomarkers to cortical atrophy in early‐onset Alzheimer's disease
Touroutoglou, Alexandra, Katsumi, Yuta, Hensel, Jennifer, Schindler, Suzanne E., Ibanez, Laura, Brickhouse, Michael, Eloyan, Ani, Eckbo, Ryan, Zaitsev, Alexander, Joie, Renaud La, Thangarajah, Maryanne, Taurone, Alexander, Vemuri, Prashanthi, Jack, Clifford R., Hammers, Dustin B., Foroud, Tatiana, Aisen, P, Ls, Beckett, Koeppe, Robert, Kukull, Walter A., Toga, Arthur, ATRI, A, Db, Clark, Day, Gregory S., Duara, Ranjan, Graff‐Radford, Neill R., Grant, Ian M., Ls, Honig, Johnson, Erik C. B., Jones, David T., Masdeu, J C, Mf, Mendez, Musiek, Erik, Onyike, Chiadi U., Riddle, Meghan, Rogalski, Emily, Salloway, Stephen, Sha, Sharon, Turner, R. Scott, Wingo, Thomas S., D, Von Dem Wolk, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Apostolova, L G, JL, Dage, Dickerson, Bradford C., Eldaief, Mark C., Joie, Renaud La , La Joie, Renaud , Touroutoglou, Alexandra , Katsumi, Yuta , Schindler, Suzanne E. , Ibanez, Laura , Brickhouse, Michael , Eloyan, Ani , Thangarajah, Maryanne, Vemuri, Prashanthi , Jack, Clifford R. , Hammers, Dustin B , Foroud, Tatiana , Aisen, Paul , Beckett, Laurel, Koeppe, Robert A. , Kukull, Walter A. , Toga, Arthur W. , Atri, Alireza, Clark, David, Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Johnson, Erik C. B. , Jones, David T. , Musiek, Erik , Onyike, Chiadi U. , Riddle, Meghan , Salloway, Stephen , Sha, Sharon J. , Turner, R. Scott, Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Dickerson, Bradford Clark , Eldaief, Mark C.

Mayo Clinic

Alzheimer's & Dementia | July 21, 2026 | Volume: 22 | Issue: 7 | Pages: No page available

10.1002/alz.71479 | PMID 42477860 Get It

Abstract INTRODUCTION Although cerebrospinal fluid (CSF) biomarkers reflect neurodegeneration in Alzheimer's disease (AD), it remains unclear whether these biomarkers track neurodegeneration in early‐onset Alzheimer's disease (EOAD). METHODS In 80 EOAD patients, we examined correlations between eight CSF biomarker levels and cortical thickness decreases within the EOAD cortical atrophy signature. Significant correlations were then entered into a multiple regression analysis. We also examined contributions of EOAD atrophy and CSF biomarkers to cognitive impairment. RESULTS The levels of four CSF biomarkers correlated to EOAD signature atrophy. Stepwise regression analyses revealed that CSF neurofilament light chain (NfL) levels best predicted EOAD signature atrophy. Multiple regression showed EOAD signature atrophy combined with CSF NfL levels explained more variance in cognitive impairment than either factor alone. DISCUSSION Within EOAD patients, CSF NfL levels relate to the magnitude of cortical atrophy, and a combination of EOAD signature atrophy and CSF NfL levels most robustly predict cognitive impairment.
Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression
Gunter, Jeffrey L., Hu, Mingzhao, Raghavan, Sheelakumari, Przybelski, Scott A. , Schwarz, Christopher G. , Lowe, Val J., Petersen, Ronald C. , Graff‐Radford, Jonathan , Jack, Clifford R., Schwarz, Christopher G , Kantarci, Kejal , Petersen, Ronald C , Graff-Radford, Jonathan , Vemuri, Prashanthi , Low, Audrey , Gunter, Jeffrey L. , Hu, Mingzhao, Raghavan, Sheelakumari , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Annals of Neurology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ana.78299 | PMID 42469606 Get It

Objective Magnetic resonance imaging (MRI)‐visible enlarged perivascular spaces (PVS) are markers of cerebral small vessel disease (SVD) and aging, processes implicated in both neurodegenerative and cerebrovascular pathologies. However, longitudinal positron emission tomography (PET) studies examining PVS as a mechanism underlying Alzheimer's disease (AD) pathophysiological progression are lacking. Our overall objective was to investigate the associations of baseline PVS burden with white matter hyperintensity (WMH) volume, amyloid‐PET, and tau‐PET, both cross‐sectionally and longitudinally. Methods We examined 2,229 participants across the aging‐AD spectrum from the Mayo Clinic Study of Aging (MCSA) and the Mayo Alzheimer's Disease Research Center (ADRC) (mean age = 68.59 ± 12.70 and 48.94% women). PVS and WMH were quantified using a novel in‐house algorithm. Amyloid on [ 11 C]Pittsburgh Compound B (PiB)‐PET and tau on AV1451‐PET were measured. Cross‐sectional regional and global associations were examined using canonical correlation analysis (CCA). Longitudinal associations were examined using age‐ and sex‐adjusted linear mixed effect (LME) models with natural splines and subject‐wise 10‐fold cross‐validation. Result Three distinct associations were observed: (1) PVS in the basal ganglia (PVS‐BG) was associated with greater WMH volume both cross‐sectionally and longitudinally; (2) PVS‐BG covaried with higher PiB standardized uptake value ratio (SUVR) cross‐sectionally, with longitudinal trajectory associations limited to amyloid‐negative individuals; (3) PVS in the centrum semiovale (PVS‐CSO) was not associated with amyloid or tau, but was associated with occipital WMH, a pattern characteristic of CAA. Interpretation Findings lend support for PVS‐BG as an early indicator of small vessel dysfunction and WMH pathogenesis. Individuals with higher PVS‐BG burden exhibited higher WMH burden and faster WMH progression, suggesting that PVS‐BG may identify individuals at increased risk of progressive SVD. Evidence linking PVS to downstream AD biomarker progression was weaker. Findings support the relevance of PVS‐CSO to CAA, suggesting that they may reflect changes occurring early in the disease process. ANN NEUROL 2026
Imaging of Complications after Prostate Interventions
Thompson, Cole P. , Takahashi, Hiroaki , Broski, S. M., Froemming, Adam T. , Takahashi, Naoki , Woodrum, David A. , Andrews, Jack R. , Kawashima, Akira , Kawashima, Akira , Thompson, Cole P. , Takahashi, Naoki , Takahashi, Hiroaki , Broski, Stephen M.

Mayo Clinic

RadioGraphics | July 16, 2026 | Volume: 46 | Issue: 8 | Pages: No page available

10.1148/rg.250116 | PMID 42461755 Get It

Imaging is integral to detection and characterization of complications after prostate interventions, including vascular, infectious, urinary, and radiation-related complications, and facilitates timely diagnosis and management.
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

Mayo Clinic

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.
Comparing Harmonization Approaches for Protocol-Related Variability in Multisite Diffusion MRI Data
Liou, Kenny , Thomopoulos, Sophia I. , Reina, Julio E Villalon, Yoo, Hannah, Shuai, Yuhan , Chehrzadeh, Sasha, Arani, Arvin, Borowski, Bret, Reid, Robert I. , Weiner, Michael, Jahanshad, Neda , Thompson, Paul M., Nir, Talia M., Vemuri, Prashanthi , Jack, Clifford R , Reid, Robert I , Thomopoulos, Sophia I , Reina, Julio E Villalon, Arani, Arvin , Vemuri, Prashanthi , Jack, Clifford R. , Weiner, Michael W , Thompson, Paul M. , Nir, Talia M.

Mayo Clinic

No container title available | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.07.737018 | PMID 42465495 Get It

Diffusion MRI (dMRI) enables assessment of white matter microstructural abnormalities in Alzheimer's disease (AD), and multisite datasets enable more robust modeling of non-biological variation that can confound analyses. The Alzheimer's Disease Neuroimaging Initiative (ADNI) includes over 10 dMRI protocols, necessitating robust methods to model protocol-related variability when pooling data. Here, we compared three harmonization approaches: (1) mixed-effects models, (2) ComBat-GAM, and (3) eHarmonize, a reference-based lifespan method. We assessed their ability to reduce protocol-related variability in diffusion tensor imaging fractional anisotropy (FA) and mean diffusivity (MD) while preserving associations with cognitive impairment (CI), and amyloid-beta (Aβ) and tau PET burden in 1,086 ADNI3/4 participants. All approaches yielded more closely aligned FA/MD distributions across protocols. Associations with clinical indicators of CI were highly consistent across approaches, whereas PET associations were less widespread and more variable. Overall, multiple strategies effectively modeled protocol-related variability while preserving AD-related associations.
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone, Lena E. , Logan, Brent R. , Liu, Xuerong , Williams, Olatundun , Dunn, Elizabeth A. , Thakar, Monica S. , Kidd, Sharon A. , Dorsey, Morna J. , O'Reilly, R, Kapoor, Neena , Kapadia, Malika , Jyonouchi, Soma , Chandra, Sharat , Chellapandian, Deepak , Chaudhury, Sonali , Chen, Karin , Rayes, Ahmad , Quigg, Troy C. , Teira, Pierre , Gillio, Alfred P. , Eissa, Hesham, Knutsen, Alan P., Aquino, Victor M. , Shereck, Evan , Lugt, Mark T. Vander , Rozmus, Jacob, Yu, Lolie C. , Shah, Ami J. , Joshi, Avni Y. , Buckley, Rebecca H. , Oved, Joseph H. , Azim, Hisham Abdel, Martinez, Caridad , Sullivan, Kathleen E. , Bleesing, Jack J., Madden, Lisa, Shenoy, Shalini , Seroogy, Christine M. , Rubin, Tamar N. , Licata, Jennifer, Andolina, Jeffrey R. , Burroughs, Lauri M. , Leiding, Jennifer W. , Marsh, Rebecca , Pai, Sung‐Yun , Torgerson, Troy R. , Heimall, Jennifer , Griffith, Linda M. , Puck, Jennifer M. , Dvorak, Christopher C. , Cowan, Morton J. , Liu, Xuerong , Mousallem, Talal , Dorsey, Morna J , O'Reilly, Richard J , Kapoor, Neena , Forbes Satter, Lisa R , Kapadia, Malika , Chandra, Sharat , Ebens, Christen L , Chellapandian, Deepakbabu , Chaudhury, Sonali , Chen, Karin , Dávila Saldaña, Blachy J , Rayes, Ahmad , Quigg, Troy C , Chandrakasan, Shanmuganathan , Bednarski, Jeffrey J , DeSantes, Kenneth B , Teira, Pierre , Gillio, Alfred P , Eissa, Hesham , Aquino, Victor M , Shereck, Evan B , Moore, Theodore Bruce , Caywood, Emi H , Vander Lugt, Mark T , Rozmus, Jacob , Broglie, Larisa A , Yu, Lolie C. , Shah, Ami J , Joshi, Avni Y , Buckley, Rebecca H , Dara, Jasmeen , Oved, Joseph H , Abdel Azim, Hisham , Martinez, Caridad , Prockop, Susan E , Sullivan, Kathleen E , Bleesing, Jack J , Keller, Michael D , Madden, Lisa M , Parikh, Suhag , Shenoy, Shalini , Seroogy, Christine M , Rubin, Tamar , Licata, Jennifer , Andolina, Jeffrey R , Kohn, Donald B , Burroughs, Lauri M , Leiding, Jennifer W , Marsh, Rebecca A , Notarangelo, Luigi D , Pai, Sung-Yun , Torgerson, Troy R , Pulsipher, Michael A. , Heimall, Jennifer , Cuvelier, Geoffrey D E , Griffith, Linda M , Puck, Jennifer M , Dvorak, Christopher C , Cowan, Morton J , Haddad, Elie , Winestone, Lena E , Satter, Lisa Forbes , Ebens, Christen L. , Saldaña, Blachy J. Dávila , Chandrakasan, Shanmuganathan , Knutsen, Alan P. , Broglie, Larisa , Dara, Jasmeen , Abdel‐Azim, Hisham , Prockop, Susan E. , Bleesing, Jack , Keller, Michael D. , Parikh, Suhag , Kohn, Donald B. , Cuvelier, Geoff D.E. , Haddad, Élie

Mayo Clinic

Journal of Human Immunity | July 7, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20250231 | PMID 42416786 Get It

Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
Canine-Associated Capnocytophaga canimorsus Bacteremia in an Older Adult Without Classical Immunosuppressive Risk Factors
Hirte, Ingrid L. , McHugh, Jack W., McHugh, Jack , Miller, Nathaniel E , Hirte, Ingrid L. , McHugh, Jack , Miller, Nathaniel E.

Mayo Clinic

American Journal of Case Reports | July 6, 2026 | Volume: 27 | Issue: No issue available | Pages: No page available

10.12659/ajcr.952980 | PMID 42640881 Get It

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Gaballa, Mahmoud R. , Julian, Kelley , Afrough, Aimaz , Hansen, Doris K. , Goel, Utkarsh , Corraes, Andre De Menezes Silva, Dima, Danai , Rana, Masooma , Hosoya, Hitomi , Mikkilineni, Lekha , Fogel, Lindsay , Raza, Shahzad, Zanwar, Saurabh , Sannareddy, Aishwarya, Borogovac, Azra , Green, Kimberly M , Biran, Noa, Shune, Leyla, Ouchveridze, Evguenia, DeJarnette, Shaun, Ferreri, Christopher J, Richards, Tiffany, Bal, Susan , Ye, Jing Christine, Shain, Kenneth H. , Harada, Ken , Avila, Gabriel De, Voorhees, Peter, Khouri, Jack , Sidana, Surbhi , Lin, Yi, Patel, Krina K. , Sborov, Douglas W. , Gaballa, Mahmoud , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Zanwar, Saurabh S , Borogovac, Azra , Davis, James A , Green, Kimberly , Zolotov, Eli , Herr, Megan M. , Abid, Muhammad Bilal , Bal, Susan , Ali, Hossam M , Kaur, Gurbakhash , Shain, Kenneth H , Castaneda Puglianini, Omar , Hassan, Hamza , Anderson, Larry D , Khouri, Jack , Sidana, Surbhi , Portuguese, Andrew J , Janakiram, Murali , Lee, Hans C , Patel, Krina , Sborov, Douglas W , Dima, Danai , Hosoya, Hitomi , Rana, Masooma S , Julian, Kelley L , Hansen, Doris K , Corraes, Andre De Menezes Silva , Raza, Shahzad , Banerjee, Rahul , Pasvolsky, Oren , Sannareddy, Aishwarya , Davis, James A. , Biran, Noa , Zolotov, Eli , Shune, Leyla , Atrash, Shebli , Ferreri, Christopher J. , Richards, Tiffany, Abid, Muhammad Bilal , Ali, Hossam M. , Ye, Jing Christine, Richard, Shambavi , Kaur, Gurbakhash , Puglianini, Omar Castañeda , Rossi, Adriana , Hassan, Hamza , Anderson, Larry D. , Voorhees, Peter M. , Portuguese, Andrew J. , Janakiram, Murali , Lee, Hans C. , Grajales‐Cruz, Ariel

Mayo Clinic

Blood Advances | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020826 | PMID 42392158 Get It

Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as 'active' (≥5% circulating plasma cells within 30 days of BsAb initiation) or 'historical'. In a heavily pretreated population, patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging therapy to CAR-T (Tal Bridge, 11%). Cytokine release syndrome (CRS) was grade 1-2 in 56% and grade 3-4 in 4%, whereas neurotoxicity was grade 1-2 in 16% and grade 3-4 in 5%. Among 110 evaluable patients, the overall response rate (ORR) was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS of 1.2 and 1.6 months and mOS of 8.1 and 3.6 months, respectively (P=0.007, P=0.023). In active PCL, Tal LOT achieved mPFS/mOS of 6.9/12.2 months versus 0.7/1.4 months with teclistamab and 1.0/3.1 months with elranatamab, respectively (P&lt;0.001, P=0.002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were safe in PCL, with talquetamab showing superior outcomes compared with BCMA-directed BsAbs.
Targeting the S100A2–RAGE Pathway Restores AT2 Cell Identity and Mitigates Lung Fibrosis
Zhou, Changli , Bagherpoor, Alireza Jian, Deng, Wei, Tschumperlin, Daniel, Tan, Qi, Wellmerling, Jack H, Wellmerling, Jack , Tschumperlin, Daniel J. , Tan, Qi

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrcmb/aanag133 | PMID 42576310 Get It

Abstract Lung fibrosis, including idiopathic pulmonary fibrosis (IPF), represents a spectrum of progressive interstitial lung diseases characterized by disrupted epithelial repair, fibroblast activation, and excess extracellular matrix accumulation. A central feature of fibrotic progression is the loss of alveolar type 2 epithelial (AT2) cell identity and the emergence of aberrant transitional states that fail to support normal regeneration. Based on our re-analysis of multiple publicly available scRNA-seq datasets from the IPF Cell Atlas, S100A2 expression is tightly associated with basal-like reprogramming of AT2 cells and is a top upregulated gene at both mRNA and protein levels in IPF lungs. Furthermore, scRNA-seq data from human lung organoid models reveal that AT2 cells co-cultured with fibroblasts acquire a basal-like phenotype and express high levels of S100A2. Functionally, overexpression of S100A2 in human iPSC-derived lung alveolar epithelial type 2 (iAT2) cells leads to loss of AT2 cellular identity, increased generation of reactive oxygen species, and activation of RAGE signaling pathway. We demonstrate that pharmacologic inhibition of RAGE using Azeliragon preserves AT2 cell populations, associated with reduced oxidative stress in iAT2 cells, and significantly attenuates collagen deposition in bleomycin-induced lung fibrosis models. Collectively, our results indicate that S100A2 is a key driver of epithelial dysfunction in lung fibrosis, promoting loss of AT2 identity, aberrant basal fate acquisition, and persistent epithelial injury. Targeting the unrecognized S100A2–RAGE pathway may offer a new therapeutic strategy to restore epithelial homeostasis in lung fibrosis.